Capstone Investment Advisors
TARS icon

Capstone Investment Advisors’s Tarsus Pharmaceuticals TARS Stock Holding History

Capstone Investment Advisors’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$267K Buy
+3,799
New +$265K ﹤0.01% 1410
2025
Q4 		– Sell
-11,501
Closed -$684K – 2036
2025
Q3 		$684K Buy
+11,501
New +$566K ﹤0.01% 1190

Other funds holding TARS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capstone Investment Advisors's TARS Position: Q1 2026 in Review

Capstone Investment Advisors opened a new position in Tarsus Pharmaceuticals (TARS) in Q1 2026: 3,799 shares worth $267K. The stake represents ﹤0.01% of the portfolio and ranks #1410 among its holdings. This is a return to the name: Capstone Investment Advisors previously reported a position in TARS as recently as Q3 2025.

Capstone Investment Advisors first reported a position in TARS in Q3 2025 and has held it in 2 quarters since. The position peaked at $684K in Q3 2025. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

  • Capstone Investment Advisors held 3,799 shares of Tarsus Pharmaceuticals worth $267K as of Q1 2026.
  • Tarsus Pharmaceuticals was a new Capstone Investment Advisors position in Q1 2026.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q1 2026, its #1410 holding.
  • Capstone Investment Advisors first reported a position in Tarsus Pharmaceuticals in Q3 2025 and has held it in 2 quarters since.
  • Capstone Investment Advisors's Tarsus Pharmaceuticals position peaked at $684K in Q3 2025.
  • 253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on Capstone Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.